tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fungemia D016469 2 associated lipids
Legionellosis D007876 3 associated lipids
Lung Abscess D008169 1 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Alopecia Areata D000506 6 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Polymyositis D017285 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Blepharitis D001762 4 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Erythema Nodosum D004893 5 associated lipids
Sweet Syndrome D016463 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Deglutition Disorders D003680 2 associated lipids
Oral Ulcer D019226 1 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Epididymitis D004823 1 associated lipids
Orchitis D009920 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Citrullinemia D020159 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Hand Injuries D006230 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Pemphigus D010392 3 associated lipids
Mutism D009155 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Intestinal Atresia D007409 3 associated lipids
Priapism D011317 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
West Nile Fever D014901 1 associated lipids
Foot Ulcer D016523 4 associated lipids
Fibroadenoma D018226 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Lymphocele D008210 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Angiofibroma D018322 2 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Cheilitis D002613 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Optic Neuritis D009902 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Balanitis D001446 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Wilson CH et al. Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. 2004 Ann. Transplant. pmid:15478912
Muraki Y et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. 2011 Oct-Dec Ann. Transplant. pmid:22210422
Boratyńska M et al. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. 2006 Ann. Transplant. pmid:17494290
Foroncewicz B et al. A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. 2013 Ann. Transplant. pmid:23896824
Grochowiecki T et al. A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. 2006 Ann. Transplant. pmid:17494291
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Rhu J et al. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. 2017 Ann. Transplant. pmid:29180612
Mocchegiani F et al. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. 2014 Ann. Transplant. pmid:25347718
Fox BD et al. Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients. 2017 Ann. Transplant. pmid:29133776
Rehman S et al. Effect of different tacrolimus levels on early outcomes after kidney transplantation. 2014 Ann. Transplant. pmid:24509826
Legris T et al. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. 2013 Ann. Transplant. pmid:24231646
Hakeam HA et al. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. 2008 Ann. Transplant. pmid:18566560
Bäckman L and Persson CA An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. 2014 Ann. Transplant. pmid:24637379
Girman P et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. 2001 Ann. Transplant. pmid:11803619
Steinebrunner N et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. 2014 Ann. Transplant. pmid:24457606
Wu YJ et al. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. 2016 Ann. Transplant. pmid:26782179
Gijsen VM et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. 2012 Apr-Jun Ann. Transplant. pmid:22743729
Urbanowicz T et al. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. 2014 Ann. Transplant. pmid:25274118
Czubkowski P et al. Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation. 2014 Ann. Transplant. pmid:25409773
Baron PW et al. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. 2017 Ann. Transplant. pmid:28533501
Furmańczyk A et al. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009155
Gerlach UA et al. Aspergillus spondylodiscitis after multivisceral transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009156
Malinowski M et al. Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. 2010 Jul-Sep Ann. Transplant. pmid:20877268
Roan JN et al. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. 2013 Ann. Transplant. pmid:23792500
Tanaka T et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. 2013 Ann. Transplant. pmid:23792533
Ueda K et al. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. 2014 Ann. Transplant. pmid:24535029
El-Agroudy AE et al. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. 2008 Ann. Transplant. pmid:19034223
Augusto JF et al. Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. 2013 Ann. Transplant. pmid:23872516
Miyata Y et al. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. 2016 Ann. Transplant. pmid:27503662
Mizuno S et al. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. 2013 Ann. Transplant. pmid:23845965
Herden U et al. Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:26842532
Kuypers DR Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. 2008 Ann. Transplant. pmid:18806728
Grenda R et al. Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients--a retrospective study. 2009 Jul-Sep Ann. Transplant. pmid:19644155
Basu A et al. Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. 2011 Jul-Sep Ann. Transplant. pmid:21959503
Fukazawa K et al. Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. 2011 Jul-Sep Ann. Transplant. pmid:21959523
Zegarska J et al. Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. 2015 Ann. Transplant. pmid:26313036
Figurski MJ et al. Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. 2012 Jan-Mar Ann. Transplant. pmid:22466911
Acott P and Babel N BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? 2012 Jan-Mar Ann. Transplant. pmid:22466913
Bułanowski M et al. Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. 2012 Jul-Sep Ann. Transplant. pmid:23018257
Schmid S et al. Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection. 2014 Ann. Transplant. pmid:25123847
Baran DA and Galin ID "One size fits all": immunosuppression in cardiac transplantation. 2003 Ann. Transplant. pmid:12848376
Remiszewski P et al. Orthotopic liver transplantation for acute liver failure resulting from "acute fatty liver of pregnancy". 2003 Ann. Transplant. pmid:15114933
Ogura Y et al. Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:27432248
Dedinská I et al. Waist circumference as an independent risk factor for NODAT. 2015 Ann. Transplant. pmid:25791039
Eguchi S et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. 2007 Ann. Transplant. pmid:18344932
Zahn A et al. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. 2013 Ann. Transplant. pmid:24088725
Garaix F et al. Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. 2018 Ann. Transplant. pmid:30093607
WÅ‚odarczyk Z et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. 2002 Ann. Transplant. pmid:12465429
Matia I et al. Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. 2014 Ann. Transplant. pmid:24815872
Park S et al. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. 2018 Ann. Transplant. pmid:29891834
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Provenzani A et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. 2009 Jan-Mar Ann. Transplant. pmid:19289993
Urbanowicz T et al. Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. 2014 Ann. Transplant. pmid:24949728
Fuchs U et al. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. 2014 Ann. Transplant. pmid:24953848
Hošková L et al. Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. 2016 Ann. Transplant. pmid:27226081
Wu P et al. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. 2011 Jan-Mar Ann. Transplant. pmid:21436775
Foroncewicz B et al. Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. 2014 Ann. Transplant. pmid:25163829
Bösmüller C et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. 2012 Ann. Transplant. pmid:23274323
Olczak-Kowalczyk D et al. The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. 2012 Ann. Transplant. pmid:23274327
Zakliczyński M et al. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. 2005 Ann. Transplant. pmid:16218032
Schnitzbauer AA et al. Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation. 2015 Ann. Transplant. pmid:25553853
Mahalati K and Kahan BD Pharmacological surrogates of allograft outcome. 2000 Ann. Transplant. pmid:11217202
Garlicki M et al. Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. 2006 Ann. Transplant. pmid:17025026
Ruangkanchanasetr P et al. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. 2016 Ann. Transplant. pmid:27980321
Van Laecke S et al. Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. 2017 Ann. Transplant. pmid:28848225
Kitazawa F et al. Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. 2017 Ann. Transplant. pmid:28947731
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Hirano Y et al. Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation. 2017 Ann. Transplant. pmid:28798289
Illsinger S et al. Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. 2011 Apr-Jun Ann. Transplant. pmid:21716189
Duvoux C et al. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. 2015 Ann. Transplant. pmid:25588713
Mijal J et al. Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. 2002 Ann. Transplant. pmid:12854345
Albano L et al. Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. 2016 Ann. Transplant. pmid:27122116
Thölking G et al. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. 2016 Ann. Transplant. pmid:27003330
Snell GI et al. Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. 2013 Ann. Transplant. pmid:23921892
Wyzgał J et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. 2007 Ann. Transplant. pmid:18173063
McCourtie AS et al. Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition. 2010 Ann. Thorac. Surg. pmid:20494024
Laubach VE Invited commentary. 2010 Ann. Thorac. Surg. pmid:20494025
Li S et al. Intrathymic inoculation of donor bone marrow induces long-term acceptance of lung allografts. 2003 Ann. Thorac. Surg. pmid:12537225
Sugita M et al. Pharmacologic modulation of alveolar liquid clearance in transplanted lungs by phentolamine and FK506. 2009 Ann. Thorac. Surg. pmid:19699927
Moffatt-Bruce S Invited commentary. 2009 Ann. Thorac. Surg. pmid:19699928
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Leshnower BG et al. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. 2008 Ann. Thorac. Surg. pmid:18805178
Chambers DJ Invited commentary. 2008 Ann. Thorac. Surg. pmid:18805179
Nathan M et al. Cyclosporin A but not FK-506 protects against dopamine-induced apoptosis in the stunned heart. 2005 Ann. Thorac. Surg. pmid:15854943
Hirai T et al. A short course of FK506 can induce limited donor-specific graft acceptance. 1994 Ann. Thorac. Surg. pmid:7520685
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Oto T et al. Calcineurin inhibitor-related cholestasis complicating lung transplantation. 2010 Ann. Thorac. Surg. pmid:20417810
Groetzner J et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single center. 2005 Ann. Thorac. Surg. pmid:15620914
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Schlegel A et al. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. 2014 Ann. Surg. pmid:25243553
Colombani PM et al. Liver transplantation in infants younger than 1 year of age. 1996 Ann. Surg. pmid:8645039
Fealy MJ et al. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. 1994 Ann. Surg. pmid:7507657
Ozawa K et al. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. 1992 Ann. Surg. pmid:1280074
Vivarelli M et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. 2008 Ann. Surg. pmid:18948815
Petruzzo P et al. Outcomes after bilateral hand allotransplantation: a risk/benefit ratio analysis. 2015 Ann. Surg. pmid:24646555
Lerut J et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. 2008 Ann. Surg. pmid:19092340
Bartlett ST et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 1996 Ann. Surg. pmid:8857849